Page last updated: 2024-10-27

fluoxetine and Menopause

fluoxetine has been researched along with Menopause in 17 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.

Research Excerpts

ExcerptRelevanceReference
"This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women."9.51Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial. ( Álvarez-Pérez, MA; Bajonero-Domínguez, A; Cruz-Luna, M; Garmendia-Gallardo, C; González-Quiroz, JL; Hernández-Castañón, MY; Hernández-Hernández, VY; Loranca-Moreno, P; Ocampo-Godínez, JM; Rios-Espinosa, A; Sánchez-Tinoco, PM; Vergara Lope-Núñez, JA, 2022)
"This study aimed to determine the efficacy of non-hormonal therapy with citalopram vs fluoxetine for treating vasomotor syndrome (VMS) and urogenital syndrome of menopause (GSM) in Mexican women."5.51Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial. ( Álvarez-Pérez, MA; Bajonero-Domínguez, A; Cruz-Luna, M; Garmendia-Gallardo, C; González-Quiroz, JL; Hernández-Castañón, MY; Hernández-Hernández, VY; Loranca-Moreno, P; Ocampo-Godínez, JM; Rios-Espinosa, A; Sánchez-Tinoco, PM; Vergara Lope-Núñez, JA, 2022)
"Results from these trials indicate that paroxetine, citalopram, escitalopram, venlafaxine, and desvenlafaxine are effective in reducing the frequency and severity of hot flashes."4.91The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. ( Handley, AP; Williams, M, 2015)
" FL did not affect thermic response to oral glucose neither after acute nor chronic administration (p=NS for all groups studied)."2.69Metabolic effects of fluoxetine in obese menopausal women. ( Bertolini, M; Bondi, M; Del Rio, G; Menozzi, R; Venneri, MG, 2000)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (17.65)18.2507
2000's8 (47.06)29.6817
2010's5 (29.41)24.3611
2020's1 (5.88)2.80

Authors

AuthorsStudies
Rios-Espinosa, A1
Cruz-Luna, M1
Garmendia-Gallardo, C1
Hernández-Castañón, MY1
Hernández-Hernández, VY1
Sánchez-Tinoco, PM1
Bajonero-Domínguez, A1
Vergara Lope-Núñez, JA1
Álvarez-Pérez, MA1
González-Quiroz, JL1
Loranca-Moreno, P1
Ocampo-Godínez, JM1
Macías-Cortés, ED1
Llanes-González, L1
Aguilar-Faisal, L1
Asbun-Bojalil, J1
Coelho, GA1
Rodrigues, E1
Andersen, ML1
Tufik, S1
Hachul, H1
Kornstein, SG1
Pedersen, RD1
Holland, PJ1
Nemeroff, CB1
Rothschild, AJ1
Thase, ME1
Trivedi, MH1
Ninan, PT1
Keller, MB1
Handley, AP1
Williams, M1
Zhu, X1
Liew, Y1
Liu, ZL1
Liu, P1
He, FF2
Bai, WP1
Yu, Q2
Shi, W1
Wu, YY2
He, DJ1
Xiao, JH1
Zheng, Y1
Liao, QP1
Yin, CX1
Hui, Y1
Yu, J1
Wei, J1
Gaszner, P1
Albertazzi, P1
Epperson, CN1
Amin, Z1
Naftolin, F1
Cappiello, A1
Czarkowski, KA1
Stiklus, S1
Anderson, GM1
Krystal, JH1
Alexander, IM1
Moore, A1
Amsterdam, JD1
Garcia-España, F1
Goodman, D1
Hooper, M1
Hornig-Rohan, M1
Bondi, M1
Menozzi, R1
Bertolini, M1
Venneri, MG1
Del Rio, G1
Parry, BL1
Newton, RP1
Urban, RJ1
Veldhuis, JD1
Forrest, DV1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445]91 participants (Actual)Interventional2021-01-20Completed
Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol[NCT01635218]Phase 2133 participants (Actual)Interventional2012-03-31Completed
An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term[NCT00046020]Phase 41,096 participants (Actual)Interventional2000-08-31Completed
Interaction of Estrogen and Serotonin in Modulating Brain Activation in Menopause[NCT01208324]47 participants (Actual)Interventional2010-03-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.

17-item Hamilton Rating Scale for Depression (HRSD) is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in HRSD was assessed at baseline and after six weeks of treatment. For this study the change was calculated as the later time point (total score in 17- HRSD at 6 weeks) minus the earlier time point (total score at baseline). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Hamilton Scale (Mean)
Individualized Homeopathic Treatment9.9
Fluoxetine11.7
Placebo15

Change From Baseline in Beck Depression Inventory at 6 Weeks.

Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory that assess severity of depression. A total score range was assessed at baseline and after six weeks of treatment. A score 0 (without depression) up to 63 (most severe depression). For this study the change was calculated as the later time point (total score in BDI at 6 weeks) minus the earlier time point (total score in BDI at baseline). A score 0 - 8 is considered normal, 9 - 18 (mild to moderate depression), 19 - 28 (moderate to severe depression), > 29 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Beck Depression Inventory (Mean)
Individualized Homeopathic Treatment12
Fluoxetine14.2
Placebo15.5

Change From Baseline in Greene´s Scale at 6 Weeks.

Greene Climacteric Scale (GS) is intended to be a standard measure of core climacteric symptoms. For this study a total range was assessed at baseline and after six weeks of treatment. A total score 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). The change was calculated as the later time point (total score in GS at 6 weeks) minus the earlier time point (total score at baseline).The scale measures four separate sub-scales (anxiety, depression, somatic symptoms and sexual function). The score of the four sub-scales was summed. A total score of 0 -10 is considered without symptoms, 11 - 29 (mild symptoms), 30 - 49 (moderate symptoms) and > 50 (severe symptoms). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Green Scale (Mean)
Individualized Homeopathic Treatment18.1
Fluoxetine23.1
Placebo26.8

Remission Rates at 6 Weeks

17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Remission rate definition: 17-item Hamilton Rating Scale for Depression score < 7 points after 6 weeks of treatment. (NCT01635218)
Timeframe: 6 weeks

Interventionparticipants with a score of < 7 in HS (Number)
Individualized Homeopathic Treatment7
Fluoxetine7
Placebo2

Responder Rates at 6 Weeks.

17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Responder rate definition: a decrease of 50% or more from baseline score using 17-item Hamilton Rating Scale for Depression after six weeks treatment. (NCT01635218)
Timeframe: 6 weeks

Interventionparticipants with a decrease >50% in HS (Number)
Individualized Homeopathic Treatment24
Fluoxetine19
Placebo5

Percent Change in BOLD Signal

To replicate and extend our previous behavioral findings of an interaction between estrogen therapy (ET) and tryptophan depletion on verbal memory in a group of early menopausal women randomized to receive ET. Blood-oxygen-level dependent or BOLD signal is the outcome of BOLD imaging, which is a technique used in functional MRI. BOLD signal reflects changes in regional cerebral blood flow which delineate regional activity. A positive BOLD signal marks an increase in regional blood flow, while a negative BOLD signal marks a decrease in regional blood flow. A positive percent change means that between scans the BOLD signal i.e. blood flow in that region has increased, a negative percent change means that the BOLD signal has decreased between scans. (NCT01208324)
Timeframe: 8 weeks

Interventionpercentage of BOLD signal changes (Mean)
High Ace-.43
Low Ace.20

Reviews

5 reviews available for fluoxetine and Menopause

ArticleYear
The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
    Journal of the American Association of Nurse Practitioners, 2015, Volume: 27, Issue:1

    Topics: Adult; Aged; Citalopram; Desvenlafaxine Succinate; Female; Fluoxetine; Hot Flashes; Humans; Menopaus

2015
Chinese herbal medicine for menopausal symptoms.
    The Cochrane database of systematic reviews, 2016, Mar-15, Volume: 3

    Topics: Drugs, Chinese Herbal; Estazolam; Female; Fluoxetine; Hormone Replacement Therapy; Hot Flashes; Huma

2016
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
    The journal of the British Menopause Society, 2006, Volume: 12, Issue:1

    Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapin

2006
Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
    Journal of the American Academy of Nurse Practitioners, 2007, Volume: 19, Issue:3

    Topics: Adrenergic alpha-Agonists; Algorithms; Amines; Citalopram; Clonidine; Complementary Therapies; Cyclo

2007
Chronobiological basis of female-specific mood disorders.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001, Volume: 25, Issue:5 Suppl

    Topics: Antidepressive Agents, Second-Generation; Chronobiology Phenomena; Cross-Over Studies; Depression, P

2001

Trials

9 trials available for fluoxetine and Menopause

ArticleYear
Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.
    Archives of gynecology and obstetrics, 2022, Volume: 306, Issue:6

    Topics: Citalopram; Female; Fluoxetine; Humans; Menopause; Postmenopause; Prospective Studies; Syndrome

2022
Is metabolic dysregulation associated with antidepressant response in depressed women in climacteric treated with individualized homeopathic medicines or fluoxetine? The HOMDEP-MENOP Study.
    Homeopathy : the journal of the Faculty of Homeopathy, 2017, Volume: 106, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Fem

2017
Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:1

    Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method;

2014
Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine.
    Chinese medical journal, 2004, Volume: 117, Issue:2

    Topics: Adult; Depressive Disorder; Estrogen Replacement Therapy; Female; Fluoxetine; Humans; Menopause; Mid

2004
[Comparison of the effect of fluoxetine combined with hormone replacement therapy (HRT) and single HRT in treating menopausal depression].
    Zhonghua fu chan ke za zhi, 2004, Volume: 39, Issue:7

    Topics: Adult; Climacteric; Depressive Disorder; Estrogen Replacement Therapy; Estrogens, Conjugated (USP);

2004
About the menopausal depression.
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2005, Volume: 7, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The

2005
Metabolic effects of fluoxetine in obese menopausal women.
    Journal of endocrinological investigation, 2000, Volume: 23, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Blood Glucose; Body Temperature Regulation; Double-Blind M

2000
Chronobiological basis of female-specific mood disorders.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001, Volume: 25, Issue:5 Suppl

    Topics: Antidepressive Agents, Second-Generation; Chronobiology Phenomena; Cross-Over Studies; Depression, P

2001
A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women.
    American journal of obstetrics and gynecology, 1991, Volume: 164, Issue:1 Pt 1

    Topics: Circadian Rhythm; Female; Fluoxetine; Humans; Menopause; Middle Aged; Models, Biological; Osmolar Co

1991

Other Studies

4 other studies available for fluoxetine and Menopause

ArticleYear
Psychotherapy improved the sleep quality in a patient who was a victim of child sexual abuse: a case report.
    The journal of sexual medicine, 2013, Volume: 10, Issue:12

    Topics: Antidepressive Agents, Second-Generation; Child; Child Abuse, Sexual; Crime Victims; Female; Fluoxet

2013
The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings.
    Journal of psychopharmacology (Oxford, England), 2007, Volume: 21, Issue:4

    Topics: Adult; Affect; Cognition; Depressive Disorder, Major; Drug Therapy, Combination; Estradiol; Female;

2007
Breast enlargement during chronic antidepressant therapy.
    Journal of affective disorders, 1997, Volume: 46, Issue:2

    Topics: Breast; Breast Diseases; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Hyperplasia

1997
Reappearance of menses in a patient taking fluoxetine.
    The American journal of psychiatry, 1990, Volume: 147, Issue:2

    Topics: Female; Fluoxetine; Humans; Menopause; Menstruation; Middle Aged

1990